非小细胞肺癌分子靶向药物治疗的研究进展  

The Latest Advance in Molecular Targeted Therapy for Non-small Cell Lung Cancer

作　　者：徐晓燕[1] 解卫平 孙晓如[3] 黄普文[1] 

机构地区：[1]南京医科大学第一附属医院肿瘤内科,江苏南京210029 [2]南京医科大学第一附属医院呼吸与危重症医学科,江苏南京210029 [3]江苏省计划生育科学技术研究所,江苏南京210036

出　　处：《药学进展》2016年第11期811-817,共7页Progress in Pharmaceutical Sciences

摘　　要：非小细胞肺癌(NSCLC)为最常见的肺癌病理类型,约占肺癌总数的85%。大多数肺癌患者在确诊时已属晚期,失去手术机会,保守治疗成为其重要治疗手段,但晚期肺癌患者的预后仍不理想。近年来,分子靶向治疗在肿瘤治疗领域取得重要进展,亦有研究显示其在NSCLC的临床实践中发挥显著疗效。除表皮生长因子受体(EGFR)和间变淋巴瘤激酶(ALK)等主要基因突变之外,血管内皮生长因子(VEGF)、ROS1、c-MET、RET、K-RAS、BRAF也是目前NSCLC分子靶向治疗的相关靶点。综述NSCLC分子靶向药物治疗的研究进展,旨在为该疾病的治疗提供参考。Non-small cell lung cancer（NSCLC） is the most common pathological type of lung cancer, which accounts for about 85% of cases. Unfortunately, most patients do not have the chance to do surgery because diagnosis is always confirmed at late stage. Although conservative treatment is available as an important measure, the prognosis of advanced NSCLC patients is still unsatisfactory. In recent years, molecular targeted therapies have achieved great progress in tumor therapy and played an essential role in the clinical treatment of NSCLC. In addition to epidermal growth factor receptor（EGFR） and anaplastic lymphoma kinase（ALK）, other targets involved in the targeted therapies for NSCLC include vascular endothelial growth factor（VEGF）, ROS1, MET, RET, K-RAS and BRAF. The paper reviewed the advance in molecular targeted therapy for NSCLC, so as to provide reference for its treatment.

关 键 词：非小细胞肺癌 分子靶向治疗 表皮生长因子受体 间变淋巴瘤激酶 

分 类 号：R734.2[医药卫生—肿瘤] R979.1[医药卫生—临床医学]